Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen

What Was Tested

Researchers studied Enfuvirtide in this randomized controlled trial publication.

Analysis of covariance was used to evaluate changes in the 10 MOS-HIV scale scores and 2 summary scores.

Least-squares means for these changes were calculated and used to test for between-group differences.

Why It Was Studied

This study assessed the impact of enfuvirtide on health-related quality of life (HRQoL).

Patients enrolled in 2 phase 3 trials T-20 versus Optimized Regimen Only (TORO 1 and 2) completed the Medical Outcomes Study (MOS)-HIV questionnaire at baseline and at 4, 8, 16, and 24 weeks.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Enfuvirtide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A time span of 24 weeks appears in the methods.

What Was Measured

This study assessed the impact of enfuvirtide on health-related quality of life (HRQoL).

Patients enrolled in 2 phase 3 trials T-20 versus Optimized Regimen Only (TORO 1 and 2) completed the Medical Outcomes Study (MOS)-HIV questionnaire at baseline and at 4, 8, 16, and 24 weeks.

Topics PubMed links to this paper include Anti-HIV Agents, Enfuvirtide, HIV Envelope Protein gp41, HIV Fusion Inhibitors, HIV Infections, HIV-1 and Peptide Fragments.

What This Means in Plain Language

The paper is a randomized study of Enfuvirtide over 24 weeks.

The publication is from 2004 (Journal of acquired immune deficiency syndromes (1999)), a journal based in United States.

More context: the Enfuvirtide compound page, all human trials.